General MedicationsORALGeneric

RISEDRONATE SODIUM

Standard Dose

35MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview RISEDRONATE SODIUM is listed in Drugs@FDA under application 205066 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient RISEDRONATE SODIUM Form and strength TABLET, DELAYED RELEASE;ORAL - 35MG Sponsor IMPAX LABS INC Submission history Latest submission status date: 2023-12-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview RISEDRONATE SODIUM is listed in Drugs@FDA under application 205066 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RISEDRONATE SODIUM Form and strength TABLET, DELAYED RELEASE;ORAL - 35MG Sponsor IMPAX LABS INC Submission history Latest submission status date: 2023-12-18 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.